ScoreWhy is Arcturus Therapeutics Holdings, Inc. ?
1
Poor Management Efficiency with a low ROE of 6.34%
- The company has been able to generate a Return on Equity (avg) of 6.34% signifying low profitability per unit of shareholders funds
2
With a fall in Operating Profit of -0.43%, the company declared Very Negative results in Mar 26
- The company has declared negative results for the last 6 consecutive quarters
- NET SALES(HY) At USD 3.69 MM has Grown at -92.06%
- PRE-TAX PROFIT(Q) At USD -26.36 MM has Fallen at -112.31%
- NET PROFIT(Q) At USD -26.36 MM has Fallen at -112.31%
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -41.17%, its profits have fallen by -374%
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -41.17% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Arcturus Therapeutics Holdings, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Arcturus Therapeutics Holdings, Inc.
-43.41%
-0.82
94.65%
S&P 500
22.24%
1.91
13.23%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
47.77%
EBIT Growth (5y)
1.91%
EBIT to Interest (avg)
-48.70
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.01
Sales to Capital Employed (avg)
0.53
Tax Ratio
0.54%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
392.01%
ROE (avg)
6.34%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.90
EV to EBIT
0.46
EV to EBITDA
0.48
EV to Capital Employed
2.72
EV to Sales
-0.51
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
589.73%
ROE (Latest)
-23.21%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend0What is working for the Company
NO KEY POSITIVE TRIGGERS
-26What is not working for the Company
NET SALES(HY)
At USD 3.69 MM has Grown at -92.06%
PRE-TAX PROFIT(Q)
At USD -26.36 MM has Fallen at -112.31%
NET PROFIT(Q)
At USD -26.36 MM has Fallen at -112.31%
ROCE(HY)
Lowest at -37.01%
RAW MATERIAL COST(Y)
Grown by 109.25% (YoY
CASH AND EQV(HY)
Lowest at USD 442.28 MM
Here's what is not working for Arcturus Therapeutics Holdings, Inc.
Net Sales
At USD 3.69 MM has Grown at -92.06%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (USD MM)
Pre-Tax Profit
At USD -26.36 MM has Fallen at -112.31%
over average net sales of the previous four periods of USD -12.42 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -26.36 MM has Fallen at -112.31%
over average net sales of the previous four periods of USD -12.42 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Cash and Eqv
Lowest at USD 442.28 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Raw Material Cost
Grown by 109.25% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
